
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc is advancing its pipeline of drug candidates, specifically highlighting the potential impact of SER-270, which, if successful, could significantly enhance the company's valuation beyond current assessments based solely on SER-252. The company's proprietary POZ Platform delivery technology offers innovative advantages that can better address the challenges associated with drug development, particularly for neurological diseases and pain management. Additionally, the expanding approval footprint of enFuse suggests positive long-term market acceptance for SER-252, supporting a fundamentally optimistic outlook for the company's future financial performance.
Bears say
Serina Therapeutics reported a net loss of $0.64 per share, significantly higher than the original estimate of $0.36, indicating a worsening financial position as it prepares for full-year 2025 losses projected at $2.01 per share. The company faces multiple risks, including delays in advancing SER-252 into clinical trials, challenges in achieving regulatory approval, and competition that may hinder market uptake. Additionally, potential future partnership risks and the possibility of dilution could further undermine investor confidence in the stock.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares